$VKTX kind of disingenuous to display the safety data the way they did. Vast majority of the AEs on weight loss drugs are in titration phase. They also need to raise cash. That said, should be up a lot more than this. Long
$SRPT a technical long for the next week: 2 factors at play; 1) at close today, incentive of convert holders to layer on shorts over past week ends, and 2) move from mid-cap to small-cap index results in net buying as more money sits in small cap ETFs than mid-cap
@adar170@MattBiotech I’m never surprised anymore on coherus red days lol. More shocked alvotech isn’t down more. Was a $5 stock after last CRL and now issues could bleed to stelara?
A great pair trade right now: L $CHRS, S $ALVO …. I mean just look at those charts. Same industry. Same consensus revenue ramp. Wildly divergent chart and valuation
@AnswerReality @gamechangercap I don’t see $LLY as a likely acquirer at all. Less than 1% chance. Why would they distract from the GLP-1 and obesity opportunity with an acquisition to help drive an insulin franchise that is rapidly diminishing in importance
@wander_wealth Different way to look at this - HC spending is 20% of GDP, so he is paying a only a slightly over indexed share into the system. Another way to look at it, HC costs per capita are $13k/person. Here he is perfectly indexed. Doesn’t seem egregious
Feels like part of the problem with $LQDA is that it’s shareholders are mostly an insane retail contingent. Weak hands. Those that get shaken out by a Wedbush downgrade lol